BTV-Business Television showcases Pfizer and features Other, Emerging companies, including Avivagen

OTTAWA, ONTARIO, November 22, 2012 - Avivagen Inc. (TSXV:VIV), a wellness company, will be featured on Business Television (BTV; in Canada on November 24 and 25, 2012, and in the U.S. on November 24-30, through segments on BNN and Fox Business News, among others. The particular episode is dedicated to the healthcare industry, giving an overview of Pfizer, the world's leading biopharmaceutical company, and four emerging companies, including Avivagen. Avivagen's segment highlights our OxC-beta technology and its opportunities in the companion animal and food animal production and safety markets, with particular focus on the Oximunol(TM) Chewables supplement for companion dogs. BTV is a half-hour weekly business news program that profiles emerging publicly traded companies across Canada and the U.S.


Avivagen will be featured on BTV on the following channels:



-BNN - Saturday, Nov 24 @ 8:00pm EST & Sunday, Nov 25 @ 9:30am EST

-Bell Express Vu - Saturday, Nov 24 @ 8:00pm EST & Sunday, Nov 25 @ 9:30am EST


U.S. National:

-Fox Business News - Sunday, Nov 25 @ 5:00pm EST

-America One - Saturday, Nov 24 @ 10am EST

-Biz Television Network - Sat. Nov 24 @ 1:30pm, Sun. Nov 25 @ 1pm, Mon. Nov 26 @6:30pm EST, Wed. Nov 28 @7pm, Thurs. Nov 29 @ 10:30am and Fri. Nov 30 @ 6:30pm EST


A link to the feature is available at:


About OxC-beta and Oximunol(TM) Chewables - "Optimized Health in a Chewable Tablet"

OxC-beta is Avivagen's proprietary, concentrated source of oxidized carotenoid, containing oxidation compounds that occur extensively in the plant world in minute amounts. Results of clinical trials in animals and in vitro studies indicate OxC-beta helps support immune function, which can result in general overall health improvement. Specific benefits include better growth, utilization of feed and decreased mortality in poultry and swine. It is currently available for dogs of all ages in the form of Oximunol(TM) Chewables, which work with a dog's immune system to optimize overall health and well-being


About Avivagen

Avivagen, a wellness company, is developing and delivering products for animals and humans to assist in optimizing health and daily quality of life. Avivagen is advancing product candidates for the food animal market, companion animal market and various potential human applications. More information can be found at


Forward Looking Statements
This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. The forward-looking statements reflect the current expectations of Avivagen Inc. regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


For more information:

David Hankinson

CEO, Avivagen Inc.

Phone: 902-825-9270

[email protected]


Graham Burton, PhD

President and Co-Founder, Avivagen Inc.

Phone: 613-990-0969

[email protected]